Identification of PDZD11 as a Potential Biomarker Associated with Immune Infiltration for Diagnosis and Prognosis in Epithelial Ovarian Cancer

References

• Pavlidis N, Rassy E, Vermorken JB, et al. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiol. 2021;75:102045. doi:10.1016/j.canep.2021.102045
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–1253. doi:10.1016/S0140-6736(18)32552-2
   PubMed Web of Science ®Google Scholar
• Shah S, Cheung A, Kutka M, Sheriff M, Boussios S. Epithelial ovarian cancer: providing evidence of predisposition genes. Int J Environ Res Public Health. 2022;19(13):8113. doi:10.3390/ijerph19138113
   PubMed Web of Science ®Google Scholar
• Boussios S, Moschetta M, Tatsi K, Tsiouris AK, Pavlidis N. A review on pregnancy complicated by ovarian epithelial and non-epithelial malignant tumors: diagnostic and therapeutic perspectives. J Adv Res. 2018;12:1–9. doi:10.1016/j.jare.2018.02.006
   PubMed Web of Science ®Google Scholar
• Ghose A, McCann L, Makker S, et al. Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4. Ther Adv Med Oncol. 2024;16:17588359241233225. doi:10.1177/17588359241233225
   Web of Science ®Google Scholar
• Nabokina SM, Subramanian VS, Said HM. Association of PDZ-containing protein PDZD11 with the human sodium-dependent multivitamin transporter. Am J Physiol Gastrointest Liver Physiol Apr. 2011;300(4):G561–7. doi:10.1152/ajpgi.00530.2010
   PubMed Web of Science ®Google Scholar
• Shah J, Guerrera D, Vasileva E, Sluysmans S, Bertels E, Citi S. PLEKHA7: Cytoskeletal adaptor protein at center stage in junctional organization and signaling. Int J Biochem Cell Biol. 2016;75:112–116. doi:10.1016/j.biocel.2016.04.001
   PubMed Web of Science ®Google Scholar
• Guerrera D, Shah J, Vasileva E, et al. PLEKHA7 Recruits PDZD11 to Adherens Junctions to Stabilize Nectins. J Biol Chem. 2016;291(21):11016–11029. doi:10.1074/jbc.M115.712935
   PubMed Web of Science ®Google Scholar
• Vasileva E, Sluysmans S, Bochaton-Piallat ML, Citi S. Cell-specific diversity in the expression and organization of cytoplasmic plaque proteins of apical junctions. Ann N Y Acad Sci. 2017;1405(1):160–176. doi:10.1111/nyas.13391
   PubMed Web of Science ®Google Scholar
• Rouaud F, Tessaro F, Aimaretti L, Scapozza L, Citi S. Cooperative binding of the tandem WW domains of PLEKHA7 to PDZD11 promotes conformation-dependent interaction with tetraspanin 33. J Biol Chem. 2020;295(28):9299–9312. doi:10.1074/jbc.RA120.012987
   PubMed Web of Science ®Google Scholar
• Huxham J, Tabaries S, Siegel PM. Afadin (AF6) in cancer progression: a multidomain scaffold protein with complex and contradictory roles. Bioessays. 2021;43(1):e2000221. doi:10.1002/bies.202000221
   PubMed Web of Science ®Google Scholar
• Tabaries S, Siegel PM. The role of claudins in cancer metastasis. Oncogene. 2017;36(9):1176–1190. doi:10.1038/onc.2016.289
   PubMed Web of Science ®Google Scholar
• Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–210. doi:10.1093/nar/30.1.207
   PubMed Web of Science ®Google Scholar
• Grossman RL, Heath AP, Ferretti V, et al. Toward a shared vision for cancer genomic data. N Engl J Med. 2016;375(12):1109–1112. doi:10.1056/NEJMp1607591
   PubMed Web of Science ®Google Scholar
• Consortium GT, Thomas J, Salvatore M. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580–585. doi:10.1038/ng.2653
   PubMed Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–678. doi:10.1038/s41587-020-0546-8
   PubMed Web of Science ®Google Scholar
• Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer Apr. 2012;19(2):197–208. doi:10.1530/ERC-11-0329
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Shen W, Song Z, Zhong X, et al. Sangerbox: a comprehensive, interaction-friendly clinical bioinformatics analysis platform. Commentary. iMeta. 2022;1(3):e36. doi:10.1002/imt2.36
   Google Scholar
• Luo X, Xu J, Yu J, Yi P. Shaping immune responses in the tumor microenvironment of ovarian cancer. Front Immunol. 2021;12:692360. doi:10.3389/fimmu.2021.692360
   PubMed Web of Science ®Google Scholar
• Ning F, Cole CB, Annunziata CM. Driving immune responses in the ovarian tumor microenvironment. Front Oncol. 2020;10:604084. doi:10.3389/fonc.2020.604084
   PubMed Web of Science ®Google Scholar
• Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase 3 trial. Lancet Oncol Apr. 2015;16(4):375–384. doi:10.1016/S1470-2045(15)70076-8
   PubMed Web of Science ®Google Scholar
• Wang L, Ma Q, Yao R, Liu J. Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer. Int Immunopharmacol. 2020;79:106088. doi:10.1016/j.intimp.2019.106088
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116–1127. doi:10.1056/NEJMoa1816714
   PubMed Web of Science ®Google Scholar
• Swiderska J, Kozlowski M, Kwiatkowski S, Cymbaluk-Ploska A. Immunotherapy of ovarian cancer with particular emphasis on the PD-1/PDL-1 as target points. Cancers (Basel). 2021;13(23):6063. doi:10.3390/cancers13236063
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Odunsi K, Coukos G. Immunotherapy in Ovarian Cancer: Are We There Yet? J Clin Oncol. 2019;37(27):2460–2471. doi:10.1200/JCO.19.00508
   PubMed Web of Science ®Google Scholar
• Musacchio L, Cicala CM, Camarda F, et al. Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? ESMO Open. 2022;7(4):100536. doi:10.1016/j.esmoop.2022.100536
   PubMedGoogle Scholar
• Mahadevia H, Ponvilawan B, Al-Obaidi A, Buckley J, Subramanian J, Bansal D. Exceptional synergistic response of PARP inhibitor and immune checkpoint inhibitor in esophageal adenocarcinoma with a germline BRCA2 mutation: a case report. Ther Adv Med Oncol. 2024;16:17588359241242406. doi:10.1177/17588359241242406
   Web of Science ®Google Scholar
• Shah J, Rouaud F, Guerrera D, et al. A dock-and-lock mechanism clusters ADAM10 at cell-cell junctions to promote alpha-Toxin cytotoxicity. Cell Rep. 2018;25(8):2132–2147 e7. doi:10.1016/j.celrep.2018.10.088
   PubMed Web of Science ®Google Scholar
• Sluysmans S, Mean I, Jond L, Citi S. WW. PH and C-Terminal domains cooperate to direct the subcellular localizations of PLEKHA5, PLEKHA6 and PLEKHA7. Front Cell Dev Biol. 2021;9:729444. doi:10.3389/fcell.2021.729444
   PubMed Web of Science ®Google Scholar
• Zhang Y, Weinberg RA. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front Med. 2018;12(4):361–373. doi:10.1007/s11684-018-0656-6
   PubMed Web of Science ®Google Scholar
• Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nat Rev Cancer. 2018;18(2):128–134. doi:10.1038/nrc.2017.118
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhan H. Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Lett. 2020;468:72–81. doi:10.1016/j.canlet.2019.10.013
   PubMed Web of Science ®Google Scholar
• Padmanaban V, Krol I, Suhail Y, et al. E-cadherin is required for metastasis in multiple models of breast cancer. Nature. 2019;573(7774):439–444. doi:10.1038/s41586-019-1526-3
   PubMed Web of Science ®Google Scholar
• Venhuizen JH, Jacobs FJC, Span PN, Zegers MM. P120 and E-cadherin: double-edged swords in tumor metastasis. Semin Cancer Biol. 2020;60:107–120. doi:10.1016/j.semcancer.2019.07.020
   PubMed Web of Science ®Google Scholar
• Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662–680. doi:10.1038/s41568-020-0285-7
   PubMed Web of Science ®Google Scholar
• Li X, Liu R, Su X, et al. Harnessing tumor-associated macrophages as aids for cancer immunotherapy. Mol Cancer. 2019;18(1):177. doi:10.1186/s12943-019-1102-3
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Koyama S. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. J Immunother Canc. 2021;9(7). doi:10.1136/jitc-2021-002591
   Web of Science ®Google Scholar
• Fu C, Jiang A. Dendritic cells and CD8 T Cell immunity in tumor microenvironment. Front Immunol. 2018;9:3059. doi:10.3389/fimmu.2018.03059
   PubMed Web of Science ®Google Scholar
• Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234(6):8509–8521. doi:10.1002/jcp.27782
   PubMed Web of Science ®Google Scholar
• Truxova I, Kasikova L, Hensler M, et al. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. J Immunother Cancer. 2018;6(1):139. doi:10.1186/s40425-018-0446-3
   PubMed Web of Science ®Google Scholar
• Zhang QW, Liu L, Gong CY, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One. 2012;7(12):e50946. doi:10.1371/journal.pone.0050946
   PubMed Web of Science ®Google Scholar
• Yang L, Ning Q, Tang SS. Recent advances and next breakthrough in immunotherapy for cancer treatment. J Immunol Res. 2022;2022:8052212. doi:10.1155/2022/8052212
   PubMed Web of Science ®Google Scholar